Single-cell suspensions were prepared by mechanic dispersion and enzymatic digestion of tumor tissues. Extracellular staining was performed using fluorochrome-labeled antibodies to major histocompatibility complex (MHC) class II (AF6–120.1, #553552), CD3 (145–2C11, #11–0031-85), CD4 (RM4–5, #12–0042-82), CD8 (53–6.7, #12–0081-83), CD11b (M1/70, #45–0193-82), CD40 (1C10, #12–0401-83), CD80 (16–10A1, #11–0801-85), CD86 (GL1, #25–0862-82), Ly6C (HK1.4, #53–5932-82) or Ly6G (RB6–8C5, #25–5931-82, eBioscience, San Diego, CA) after anti-FcγIII/IIRBlock were used (#558636, BD Biosciences, Franklin, NJ). Human immune cells and PBMCs were analyzed using the following antibodies: HLA-DR (LN3, #12–9956-42), CD1c (L161, #17–0015-14), CD3 (OKT3, #11–0037-42), CD14 (61D3, #11–0149-42), CD15 (MC-480, #12–8813-42), CD16 (CB16, #17–0168-42), CD19 (HIB19, #11–0199-42), CD303 (201A, #11–9818-42). For intracellular staining, cells were fixed/permeabilized and immunostained for pSTAT3 (4/P-STAT3, #562071, BD Biosciences), FoxP3 (236A/E7, #53–4777-41, eBioscience), or Arginase-1 (SL6ARG, #IC5868F, R&D Systems, Minneapolis, MN) as previously described.(28 (link)) Fluorescence data were analyzed on BD Fortessa and an AccuriC6 Flow Cytometer (BD Biosciences) using FlowJo software (TreeStar, Ashland, OR).